摘要
Abstract
Objective To investigate the efficacy and safety of trimetazidine in treating coronary atherosclerotic heart disease patients with cardiac insufficiency. Methods 84 cases of patients with coronary atherosclerotic heart disease with cardiac insufficiency were ran-domly divided into the observation group and the control group, 42 cases in each group. The control group received conventional treat-ment, while on this basis, the observation group used trimetazidine orally, 20 mg/time, 3 times/d. 4 weeks were 1 course of treatment, and the two groups were treated for 3 consecutive courses. Results After 3 courses of treatment, the total effective rate of the observa-tion group was 90. 48% which was significantly higher than 73. 81% in the control group ( P < 0. 05 ) . After treatment, the angina pec-toris frequency, duration and nitroglycerin volume in the two groups were significantly reduced ( P < 0. 01 ) , the 6 min walk distances were significant increased ( P < 0. 01 ) , and the cardiac function indexes were significantly improved ( P < 0. 01 );the indexes between the two groups had significant difference ( P < 0. 01 ) . There was no significant difference of the incidence rate of adverse reactions between the 2 groups ( P > 0. 05 ) , with no serious adverse events occurred during the treatment. Conclusion Trimetazidine can improve the clin-ical efficacy of patients with coronary atherosclerotic heart disease with cardiac insufficiency, significant reduce angina pectoris attack and the dosage of nitroglycerin, improve cardiac function and exercise tolerance.关键词
曲美他嗪/冠状动脉粥样硬化性心脏病/心功能不全/心绞痛/左室射血分数Key words
trimetazidine/coronary atherosclerotic heart disease/cardiac insufficiency/angina pectoris/left ventricular ejection fraction分类
医药卫生
